BLX-1002

BLX-1002 is a novel small-molecule thiazolidinedione (TZD) developed by Bexel Pharmaceuticals for the treatment of type 2 diabetes mellitus and hypertriglyceridemia. Unlike conventional TZDs, BLX-1002 has no apparent affinity for peroxisome proliferator-activated receptors (PPARs), thereby avoiding the adipogenic side effects, such as weight gain and edema, typically associated with PPAR-activating agents. Its mechanism of action involves enhancing glucose-stimulated insulin secretion (GSIS) in pancreatic beta-cells through a phosphatidylinositol 3-kinase (PI3K)-dependent pathway and the activation of AMP-activated protein kinase (AMPK). This selective potentiation occurs primarily at high glucose concentrations, which minimizes the risk of hypoglycemia. The drug has been evaluated in Phase 2 clinical trials to assess its effects on glucose profiles, triglycerides, and blood pressure.